News Related to Castration-resistant Prostate Cancer

Related coverage linked through entity extraction aliases.

Novartis reports new Pluvicto data in metastatic hormone-sensitive prostate cancer

May 18, 2026

Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.

STAMPEDE Analysis Links Low On-Treatment PSA to Better Survival in Advanced Prostate Cancer

May 13, 2026

A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.